Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria for Randomization:~Inclusion Criteria:~* Adenocarcinoma of the colon documented by colonoscopy or barium enema~* Tumor either considered resectable or totally resected within 24 hours prior to study~* Randomization within 2 weeks prior to surgery or within 24 hours after surgery required~* Patients randomized after surgery must meet the following criteria:~  * Complete resection performed with no evidence of residual disease or distant metastases~ * Distal margin of tumor above the peritoneal reflection in area of rectum~ * No free perforation Intestinal obstruction allowed~ * Preliminary or complementary colostomy allowed~* Concurrent registration for E3293 strongly recommended~* Age 18 and over~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Adequate organ function based on the following tests within 2 weeks prior to randomization~  * White Blood Cell (WBC) at least 3,000/mm\^3~ * Platelet count at least 100,000/mm\^3~ * Bilirubin no greater than 2.0 mg/dL~ * Creatinine no greater than 2.0 mg/dL~* No second malignancy within 5 years except: superficial non-melanomatous skin cancer and carcinoma in situ of the cervix~* Fertile patients must use adequate contraception~Exclusion Criteria:~* Dual primary tumors~* Prior nonmalignant systemic disease that would preclude use of chemotherapy~* Pregnant or nursing~* Prior fluorouracil~* Other prior or concurrent chemotherapy for this malignancy~* Prior or concurrent radiotherapy for this malignancy~Eligibility Criteria for Re-registration for Patients Randomized Pre-operatively:~* Must have pathologic classification of Dukes' B2, B3, or C disease by the contributing institution.~* Must be re-registered \< 35 days after surgery.~* ECOG performance status of 0-2.~* Complete resection must have been performed with no evidence of residual disease or distant metastasis.~* Distal margin of the tumor must not extend below the peritoneal reflection in the area of the rectum.~* Single primary colon carcinoma without free perforation demonstrated. Patients with intestinal obstruction are eligible. Preliminary or complementary colostomy dose not preclude entry of a patient.~* Have WBC \> 3000/mm\^3, platelets \> 100,000/mm\^3, adequate renal (serum creatinine \<= 2.0mg/dL) and hepatic function (bilirubin \<= 2.0mg/dL), within one week prior to beginning adjuvant chemotherapy (For Dukes' B3 and C patients only).~Eligibility Criteria for Re-registration for Patients Randomized Post-operatively:~* Must have pathologic classification of Dukes' B2, B3, or C disease by the contributing institution.~* Patient must be re-registered \< 35 days after surgery.~* ECOG performance status of 0-2.~* Started perioperative 5-FU, if assigned, within 24 hours of surgery.~* Have WBC \> 3000/mm\^3, platelets \> 100,000/mm\^3, adequate renal (serum creatinine \<= 2.0mg/dL) and hepatic function (bilirubin \< =2.0mg/dL), within one week prior to beginning adjuvant chemotherapy (For Dukes' B3 and C patients only).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perioperative 5-FU (Type: EXPERIMENTAL): Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m\^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m\^2 IV push on days 1-5
- No perioperative 5-FU (Type: ACTIVE_COMPARATOR): Patients receive no perioperative fluorouracil.~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m\^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m\^2 IV push on days 1-5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues